On 23 June 2016, the UK voted to leave the EU and, thereby, decided for Brexit. As of today, it is still uncertain what the exact implications of this decision will be, including important questions regarding how the political and legal nature of the future relationship between the UK and the EU will be.
IP: Brexit and patents
OpinionOn 23 June 2016, the UK voted to leave the EU and, thereby, decided for Brexit. As of today, it is still uncertain what the exact implications of this decision will be, including important questions regarding how the political and legal nature of the future relationship between the UK and the EU will be.
Sepsis: Adrenomed receives approval for POC study in patients with early septic shock
Latest NewsGermany is the first country that has granted full approval to Adrenomed to conduct a Phase II study with the monoclonal antibody adrecizumab in patients with early septic shock. Within the ADR-02 study, 300 patients will be enrolled in Germany, Belgium, France and the Netherlands for proof of safety and efficacy.
CDPQ acquires stake in Sebia
Latest NewsCaisse de dépôt et placement du Québec (CDPQ) is set to acquire a minority stake in diagnostic electrophoresis player Sebia Group from private equity investors Astorg and Montagu.
Swiss Roivant bags US$1.1bn financing
Latest NewsSerial drug licensee Roivant Sciences GmbH (Basel) has cashed in US$1.1bn (€937m) in an equity financing led by SoftBank Vision Fund and co-financed by existing investor Dexcel Pharma.
Voluntary health agency jump-starts Selvita’s SEL120 programme
Latest NewsThe Leukemia & Lymphoma Society (LLS) and Polish drug developer Selvita SA have entered a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukaemia (AML).
LEO orders Hitgen to discover new leads
Latest NewsIn a multi-year collaboration with LEO Pharma A/S, Chinese Hitgen is poised to discover novel small molecule leads for multiple therapeutic targets chosen by the Danish skin treatment specialist.
Acquisition: Thermo enters CMO world
BackgroundLab equipment giant Thermo Fisher Scientific Inc. is growing even bigger.
Uniqure’s new COO to oversee GMP
AppointmentsGene therapy specialist Uniqure NV announced new executive appointments to its leadership team and nominations to its Board of Directors. Scott McMillan, for instance, will be responsible for all current Good Manufacturing Process (cGMP) activities and all product development functions.
Vernalis receives next veto by FDA
Latest NewsBritish biotech company Vernalis has to deal with another Complete Response Letter by US authority FDA – this time regarding the New Drug Application for its cough and cold treatment CCP-08.
Hansa’s immunomodulatory enzyme does the job
Latest NewsSweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.